Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Hutchmed (HCM) Share Price

Price 225.00p on 12-01-2026 at 19:30:06
Change 8.00p 3.69%
Buy 224.00p
Sell 211.00p
Last Trade: Buy 10.00 at 225.00p
Day's Volume: 25,444
Last Close: 225.00p
Open: 225.00p
ISIN: KYG4672N1198
Day's Range 211.00p - 225.00p
52wk Range: 187.50p - 292.00p
Market Capitalisation: £1.93b
VWAP: 212.92786p
Shares in Issue: 859.52m

Hutchmed (HCM) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 10 225.00p Suspected BUY Trade
16:35:04 - 12-Jan-26
Buy* 58 223.00p Automatic Execution
16:29:28 - 12-Jan-26
Buy* 58 223.00p Automatic Execution
16:29:28 - 12-Jan-26
Unknown* 0 223.00p SI Trade
15:53:20 - 12-Jan-26
Buy* 39 220.00p Automatic Execution
15:07:55 - 12-Jan-26
Buy* 211 211.00p Automatic Execution
15:07:55 - 12-Jan-26
Buy* 500 211.00p Automatic Execution
15:07:55 - 12-Jan-26
Buy* 250 211.00p Automatic Execution
15:07:55 - 12-Jan-26
Buy* 175 211.00p Automatic Execution
15:07:55 - 12-Jan-26
Buy* 525 211.00p Automatic Execution
15:07:55 - 12-Jan-26
See more Hutchmed trades

Hutchmed (HCM) Share Price History

Time period:
to
Date Open High Low Close Volume
12th Jan 2026 (Mon) 225.00 225.00 211.00 225.00 25,444
9th Jan 2026 (Fri) 218.00 218.00 215.00 217.00 9,470
8th Jan 2026 (Thu) 214.00 218.00 214.00 218.00 8,809
7th Jan 2026 (Wed) 210.00 218.00 210.00 214.00 18,547
6th Jan 2026 (Tue) 201.00 211.00 201.00 211.00 9,712
5th Jan 2026 (Mon) 208.00 208.00 195.00 202.00 40,592
2nd Jan 2026 (Fri) 201.00 204.00 200.00 204.00 12,575
1st Jan 2026 (Thu) 208.00 208.00 208.00 208.00 0
31st Dec 2025 (Wed) 199.00 209.00 199.00 208.00 18,573
30th Dec 2025 (Tue) 192.00 198.50 192.00 198.50 34,925
29th Dec 2025 (Mon) 199.00 199.50 193.00 199.00 17,892
26th Dec 2025 (Fri) 196.50 196.50 196.50 196.50 0
25th Dec 2025 (Thu) 196.50 196.50 196.50 196.50 0
24th Dec 2025 (Wed) 196.50 196.50 196.50 196.50 1,030
23rd Dec 2025 (Tue) 198.00 198.00 193.00 193.00 1,777
22nd Dec 2025 (Mon) 196.50 198.00 195.00 198.00 13,824
19th Dec 2025 (Fri) 204.00 204.00 199.00 199.00 29,912
18th Dec 2025 (Thu) 200.00 204.00 200.00 204.00 24,333
17th Dec 2025 (Wed) 200.00 202.00 200.00 202.00 12,753
16th Dec 2025 (Tue) 195.50 200.00 195.50 200.00 41,894
15th Dec 2025 (Mon) 204.00 204.00 204.00 201.25 4,744
See more Hutchmed price history

Hutchmed (HCM) Regulatory News

Date Source Headline
7th Jan 2026 7:00 am RNS-R Positive Topline Results of Phase III Trial
5th Jan 2026 7:00 am RNS-R Surufatinib + Camrelizumab PDAC Phase 3 initiation
31st Dec 2025 7:00 am RNS Total Voting Rights
31st Dec 2025 7:00 am RNS Total Voting Rights
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
30th Dec 2025 10:00 am RNS-R China NDA Acceptance-Savolitinib in Gastric Cancer
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
29th Dec 2025 8:30 am RNS-R NDA Acceptance in China for Fanregratinib
29th Dec 2025 8:30 am RNS Blocklisting Six Monthly Return
See more Hutchmed regulatory news

Hutchmed (HCM) Share News

Hutchmed China hails sovleplenib results for form of anaemia in China

7th Jan 2026 11:41

(Alliance News) - Hutchmed China Ltd on Wednesday announced topline results of a phase 3 trial of its selective small molecule inhibitor sovleplenib, in a form of anaemia. Read More

Hutchmed China kicks off phase three stage of pancreatic cancer trial

5th Jan 2026 10:45

(Alliance News) - Hutchmed China Ltd on Monday said it has started the phase three part of a trial evaluating surufatinib and camrelizumab for the treatment of pancreatic cancer in China. Read More

Hutchmed savolitinib NDA for gastric cancer accepted in China

30th Dec 2025 11:21

(Alliance News) - Hutchmed China Ltd on Tuesday said Chinese regulators have accepted and granted priority review to its new drug application for savolitinib to treat certain patients with advanced gastric cancer, marking another regulatory step forward for the targeted therapy. Read More

Hutchmed drug gains China priority review for bile duct cancer

29th Dec 2025 10:51

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status. Read More

Hutchmed China kicks off clinical development of ATTC candidate

17th Dec 2025 13:25

(Alliance News) - Hutchmed China Ltd on Wednesday said it has begun the global phase one clinical development programme for its targeted cancer therapy for patients with solid tumours. Read More

See more Hutchmed news
FTSE 100 Latest
Value10,140.70
Change16.10

Login to your account

Forgot Password?

Not Registered